:
This review focuses on 5 new anti-VEGF drugs in advanced stage of clinical
development (i.e. phase 3): conbercept, brolucizumab, port delivery system with
ranibizumab, abicipar pegol and faricimab.
Results of clinical trials and advantages of each drug compared to the available
molecules are discussed in detail.